Skip to content

Study · Randomized controlled trial · n = 63 · 2001

3 results

A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis.

Hay JE, Malinchoc M, Dickson ER

Journal of hepatology1 Feb 2001Cited by 29 (Europe PMC)

PMID11281559 (opens in a new tab)DOI10.1016/s0168-8278(00)00093-3 (opens in a new tab)PepBankPUB-11281559
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    After liver transplantation, lumbar BMD fell equally with salmon calcitonin and no therapy at 4 months.

    In plain wordsAfter liver transplantation, spine bone density fell equally with salmon calcitonin and no therapy at 4 months.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeLumbar spine BMD at 4 months
    Study

    n = 63

    Comparator
    No therapy
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU/day · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Baseline BMD
    0.85 g/cm2
    calcitonin, n = 29
    BMD at 4 months
    0.81 g/cm2
    calcitonin
    Baseline BMD
    0.88 g/cm2
    controls, n = 34
    BMD at 4 months
    0.82 g/cm2
    controls

    Source sentences

    Summary
    The bone mineral density of the lumbar spine fell equally at 4 months in both groups, from 0.85 to 0.81 g/cm2 in calcitonin-treated patients (n = 29) and from 0.88 to 0.82 g/cm2 in controls (n = 34); at 12 months, both groups had stabilized to 0.83 g/cm2.
    1 context sentence
    Summary · context
    Sixty-three patients undergoing OLT for primary biliary cirrhosis (n = 26) and primary sclerosing cholarigitis (n = 37) were randomized to receive: (a), 100 IU/day of salmon calcitonin subcutaneously for the first 6 months posttransplant; or (b), no therapy.
  2. 02HumanRandomized controlled trialEfficacy outcome

    After liver transplantation, lumbar BMD stabilized at 0.83 g/cm2 with both salmon calcitonin and no therapy at 12 months.

    In plain wordsAt 12 months after liver transplantation, spine bone density stabilized at the same level with salmon calcitonin and no therapy.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeLumbar spine BMD at 12 months
    Study

    n = 63

    Comparator
    No therapy
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU/day · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    BMD at 12 months
    0.83 g/cm2
    both groups

    Source sentences

    Summary
    The bone mineral density of the lumbar spine fell equally at 4 months in both groups, from 0.85 to 0.81 g/cm2 in calcitonin-treated patients (n = 29) and from 0.88 to 0.82 g/cm2 in controls (n = 34); at 12 months, both groups had stabilized to 0.83 g/cm2.
    1 context sentence
    Summary · context
    Sixty-three patients undergoing OLT for primary biliary cirrhosis (n = 26) and primary sclerosing cholarigitis (n = 37) were randomized to receive: (a), 100 IU/day of salmon calcitonin subcutaneously for the first 6 months posttransplant; or (b), no therapy.
  3. 03HumanRandomized controlled trialEfficacy outcome

    After liver transplantation, fracturing was the same with salmon calcitonin and no therapy.

    In plain wordsAfter liver transplantation, fractures were the same with salmon calcitonin and no therapy.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeFracturing
    Study

    n = 63

    Comparator
    No therapy
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 IU/day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Fracturing was the same in both groups.
    1 context sentence
    Summary · context
    Sixty-three patients undergoing OLT for primary biliary cirrhosis (n = 26) and primary sclerosing cholarigitis (n = 37) were randomized to receive: (a), 100 IU/day of salmon calcitonin subcutaneously for the first 6 months posttransplant; or (b), no therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.